| Study Name | Description | Trial Category | Trial SubCategory |
|---|---|---|---|
| EA3161 | A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA | Cancer | Head and Neck |
| EA5163: INSIGNA | A Randomized Phase III Study of First-line Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Post-progression in Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC) with Immuno-biomarker SIGNature-driven Analysis | Cancer | Lung |
| EA5181 | Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC | Cancer | Lung |
| GOG-0263 | Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy | Cancer | Gynecologic |
| Improving Continuous Positive Airway | Improving Continuous Positive Airway Pressure Adherence in Patients with Obstructive Sleep Apnea: Impact of Patient and Family Engagement (Improving CPAP Adherence | Pulmonary | Respiratory |
| LUNGMAP | A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study) | Cancer | Lung |
| Merck Keynote MK3475-671 | A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/- Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable IIB or IIIA Non-small Cell Lung Cancer | Cancer | Lung |
| Microbiome: Correlation between Gut Microbiome and Response to Immunotherapy in Cancer Patients. | Sparrow and MSU feasibility study to establish the relationship between the success/failure of checkpoint inhibitor therapy and gut biome of cancer patients. Adults prior to starting immunotherapy or healthy adult volunteers. | Cancer | All tumor types |
| NRG-BR004 | A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer | Cancer | Metastatic Breast |
| NRG-GI004 | Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy With or Without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer | Cancer | Gastrointestinal |
| NRG-GI005 | Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA) | Cancer | Gastrointestinal |
| NRG-GY018 | A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer | Cancer | Endometrial |
| NRG-GY019 | Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum https://clinicaltrials.gov/ct2/show/NCT03797326?term=NCT03797326&draw=2&rank=1 | Cancer | Ovarian |
| NRG-HN001 | Randomized Phase II AND Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA) | Cancer | Nasopharynx Carcinoma |
| NRG-HN004 | Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) Vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin | Cancer | Head and Neck |
| NRG-HN005 | A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients with Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer | Cancer | Head and Neck |
| NRG-LU002 | Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung – Cancer | Cancer | Lung |
| NRG-LU005: Limited Stage Small Cell Lung Cancer | A Phase II/III Randomized Study of Chemoradiation VS Chemoradiation Plus Atezolizumab | Cancer | Lung |
| NRG-LU007 | RAndomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR trial | Cancer | Lung |
| NSABP FB-12: | An Open-Label Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel Plus Trastuzumab and Pertuzumab in Early Stage HER2-Negative Breast Cancer Patients Selected with a Test Measuring Live Cell HER2 Signaling Transduction (FACT 1) | Cancer | Breast |
| ON-TRK | Prospective Non-interventional study in patients with locally advanced or metastatic TRK fusion cancer treated with larotrectinib | Cancer | Genomic |
| PFO Occulder (PAS) | The purpose of this research study is to evaluate the commercially available AmplatzerTM PFO Occluder and AmplatzerTM TalismanTM PFO Occluder in preventing another stroke by closing patients patent foramen ovale (PFO). | Heart & Vascular | Structural Heart Disease |
| Portico NG | This is a study of an updated Portico Valve for TAVR. | Heart & Vascular | Structural Heart Disease |
| RTOG-0724 | Phase III Randomized Study Of Concurrent Chemotherapy and Pelvic Radiation Therapy With Or Without Adjuvant Chemotherapy In High-Risk Patients With Early-Stage Cervical Carcinoma Following Radical Hysterectomy | Cancer | Gynecologic |
| S1608 | Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma | Cancer | Hematology |
| S1703 | Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer | Cancer | Breast |
| S1706 | A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer | Cancer | Breast |
| S1801 | A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk Melanoma | Cancer | Melanoma |
| S1806 | Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer | Cancer | Genitourinary GU |
| Sync AV | This is a new CRT with optimization turned on or off. | Heart & Vascular | Cardiac Arrhythmia |
Unsupported Browser! This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.